SRINAGAR: Jammu-based lawyer Deepika Pushkar Nath, who represented the family of the eight-year-old victim in the 2018 Kathua ...

强生（Johnson & Johnson）近日宣布，美国FDA已批准口服多肽疗法Icotyde（icotrokinra），用于一线治疗中重度斑块状银屑病（PsO）成人患者，以及12岁及以上、体重至少40 kg，且适合接受全身治疗或光疗的儿童患者。

Around-the-clock performances presented using cutting-edge holograms intended to show hundreds of thousands of visitors ...

Woman lawyer of Kathua case alleges security downgrade, pulls out daughter from school ...

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...

The Delhi High Court has stayed trial court proceedings against Bina Modi and Lalit Bhasin, who were summoned in an assault ...

强生（Johnson & Johnson）今日宣布，美国FDA已批准口服多肽疗法Icotyde（icotrokinra），用于一线治疗中重度斑块状银屑病（PsO）成人患者，以及12岁及以上、体重至少40 ...

In a year in which it received a record number of applications for the incoming first-year class, Boston College continued to solidify its status as one of the country’s most selective universities.

斑块状银屑病是一种免疫介导的疾病，全球患者超过1.25亿，其中近四分之一属中重度病例，对患者身心健康及生活质量造成显著负担。近日，在银屑病领域，迎来重磅消息。 3月18日，强生宣布FDA已批准icotrokinra(商品名：ICOTYDE™)上市，用于治疗适合系统治疗或光疗的成人和12岁及以上体重≥40kg青少年中重度斑块状银屑病患者。 Icotrokinra是强生斥资近 10 亿美元从 Prot ...

From the get-go it's a shocker of a lawsuit, starting with the parties involved, Board of County Commissioners of the County ...